Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer: A systematic review and meta-analysis
Breast Disease2016Vol. 36(2-3), pp. 91–101
Citations Over TimeTop 24% of 2016 papers
Ahmed Elgebaly, Ahmed Menshawy, Gehad El Ashal, O Z Elzankaly Osama, Esraa Ghanem, Ahmed Omar, Ahmed Negida
Abstract
Current evidence shows that sunitinib, either alone or in combination with chemotherapy, has no clinical benefit for patients with advanced breast cancer. However, previous studies did not considered patient stratification and outcome assessment based on molecular markers. In terms of safety, toxicity was common with sunitinib treatment.
Related Papers
- → Novel combination of serum microRNA for detecting breast cancer in the early stage(2016)358 cited
- → PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis.(2015)76 cited
- → Elevated miR-21 is associated with poor prognosis in non-small cell lung cancer: a systematic review and meta-analysis.(2018)16 cited
- Effect of Pre-hospital Thrombolysis on Mortality in Patients with Myocardial Infarction: A Systematic Review and Meta-analysis(2018)
- → Prognostic significance of p16INK4a alteration in soft tissue sarcomas: A meta-analysis(2017)